DNAzyme targeting RIP3 suppresses NLRP3-mediated necroinflammation for the treatment of inflammatory diseases.
10.1016/j.apsb.2025.09.002
- Author:
Jiaxin JIA
1
;
Hugang ZHANG
1
;
Guangxu FANG
1
;
Yang LI
1
;
Kai WEN
1
;
Hanyu LIU
1
;
Haobo HAN
1
;
Quanshun LI
1
Author Information
1. Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.
- Publication Type:Journal Article
- Keywords:
DNAzyme;
Gene therapy;
Inflammatory diseases;
MCC950;
NOD-like receptor family pyrin domain-containing 3;
Necroinflammation;
Polyamidoamine;
Receptor-interacting protein kinase 3
- From:
Acta Pharmaceutica Sinica B
2025;15(11):5908-5932
- CountryChina
- Language:English
-
Abstract:
Necroptosis, a form of programmed cell death, initiates a series of biological responses and further culminates in necroinflammatory processes, consequently limiting the efficacy of cytokine antagonists in treating inflammatory diseases. To address this issue, DNAzyme R3-Dz specifically targeting receptor-interacting protein kinase 3 (RIP3) mRNA, a necrosome component, has been successfully developed and studied to elucidate the mechanism in cleaving its target mRNA. Then a polyamidoamine (PAMAM) derivative was constructed through the modification of nucleobase analog (termed AP) to achieve the R3-Dz delivery to macrophages. The AP/R3-Dz nanoparticles effectively downregulated the RIP3 expression, leading to subsequent decrease in the levels of reactive oxygen species (ROS) and damage-associated molecular patterns (DAMPs), ultimately inhibiting the necroinflammatory processes mediated by the NOD-like receptor family pyrin domain-containing 3 (NLRP3). Finally, AP/R3-Dz nanoparticles and their combination with the NLRP3 inhibitor MCC950 suppressed the necrotic phenotype and ameliorated the disease progression in diverse models, including gouty arthritis, autoimmune hepatitis and rheumatoid arthritis. In summary, the AP/R3-Dz nanoparticles in combination with MCC950 have been demonstrated to achieve the intervention in necroptosis and inflammation by dual disruption of the intricate feedback loop of necroinflammation and thus have promising potential in the treatment of inflammatory diseases.
